Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Dec 1;13(6):1010-1014.
doi: 10.21037/hbsn-24-418. Epub 2024 Nov 13.

Validating the prognostic value of muscle changes in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt

Zhang Wen  1   2 , Shuyue Tuo  1   2 , Ying Liu  1   2 , Jia Yuan  1   2 , Yong Li  1   2 , Lu Li  1   2 , Shejiao Dai  1   2 , Xinxing Tantai  1   2
Affiliations
Editorial

Validating the prognostic value of muscle changes in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt

Zhang Wen et al. Hepatobiliary Surg Nutr. .
No abstract available

Keywords: Cirrhosis; myosteatosis; sarcopenia; survival; transjugular intrahepatic portosystemic shunt (TIPS).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-24-418/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Typical CT images of muscle changes. (A) Patients without muscle changes; (B) patients with isolated sarcopenia; (C) patients with isolated myosteatosis; (D) patients with combined sarcopenia and myosteatosis. SMI, skeletal muscle index; MR, muscle radiodensity; CT, computed tomography; HU, Housefield unit.
Figure 2
Figure 2
Associations between muscle changes and adverse outcomes in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt. (A) Cumulative incidence of death in four patient subgroups according to the type of muscle changes during the entire follow-up period. (B) Cumulative incidence of first decompensation events, with death as competing risk, in four patient subgroups according to the type of muscle changes during the entire follow-up period. (C) Cumulative incidence of further decompensation events, with death as competing risk, in four patient subgroups according to the type of muscle changes during the entire follow-up period. (D) Adjusted hazard ratios of muscle changes for the risk of death, first and further decompensation during a 1-year period. MELD, hepatic encephalopathy and ascites were adjusted. (E) Adjusted hazard ratios of muscle changes for the risk of death, first and further decompensation during the entire follow-up period. MELD, hepatic encephalopathy and ascites were adjusted. Like in the study by Di Cola et al. (1), muscle changes were included in the model as a discrete variable scored as follows: no changes = 0, isolated sarcopenia = 1, isolated myosteatosis = 2, and combined sarcopenia and myosteatosis = 3. MELD, Model of End Stage Liver Disease; HR, hazard ratio; CI, confidence interval.
See this image and copyright information in PMC

Comment on

  • Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis.
    Di Cola S, D'Amico G, Caraceni P, Schepis F, Loredana S, Lampertico P, Toniutto P, Martini S, Maimone S, Colecchia A, Svegliati Barone G, Alessandria C, Aghemo A, Crocè SL, Adinolfi LE, Rendina M, Lapenna L, Pompili E, Zaccherini G, Saltini D, Iavarone M, Tosetti G, Martelletti C, Nassisi V, Ferrarese A, Giovo I, Masetti C, Pugliese N, Campigotto M, Nevola R, Merli M; EpatoSarco working group. Di Cola S, et al. J Hepatol. 2024 Oct;81(4):641-650. doi: 10.1016/j.jhep.2024.05.020. Epub 2024 May 21. J Hepatol. 2024. PMID: 38782120

References

    1. Di Cola S, D'Amico G, Caraceni P, et al. Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis. J Hepatol 2024;81:641-50. 10.1016/j.jhep.2024.05.020 - DOI - PubMed
    1. Tantai X, Liu Y, Yeo YH, et al. Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis. J Hepatol 2022;76:588-99. 10.1016/j.jhep.2021.11.006 - DOI - PubMed
    1. Bosch J. Small diameter shunts should lead to safe expansion of the use of TIPS. J Hepatol 2021;74:230-4. 10.1016/j.jhep.2020.09.018 - DOI - PubMed
    1. Tachi Y, Kozuka A, Hirai T, et al. Impact of myosteatosis on skeletal muscle volume loss in patients with chronic liver disease. J Gastroenterol Hepatol 2018;33:1659-66. 10.1111/jgh.14133 - DOI - PubMed
    1. Kamimura H, Sato T, Natsui K, et al. Molecular Mechanisms and Treatment of Sarcopenia in Liver Disease: A Review of Current Knowledge. Int J Mol Sci 2021;22:1425. 10.3390/ijms22031425 - DOI - PMC - PubMed